Humana Inc (HUM) Forecasted to Post Q2 2018 Earnings of $3.46 Per Share
Humana Inc (NYSE:HUM) – Equities researchers at Oppenheimer increased their Q2 2018 earnings estimates for Humana in a note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn now anticipates that the insurance provider will post earnings per share of $3.46 for the quarter, up from their prior estimate of $3.44. Oppenheimer also issued estimates for Humana’s Q3 2018 earnings at $3.37 EPS, Q4 2018 earnings at $2.38 EPS, Q1 2019 earnings at $3.29 EPS, Q2 2019 earnings at $3.94 EPS, Q3 2019 earnings at $3.84 EPS, Q4 2019 earnings at $2.68 EPS and FY2019 earnings at $13.75 EPS.
A number of other analysts also recently issued reports on HUM. Cowen reissued an “outperform” rating and set a $275.00 price target (up from $230.00) on shares of Humana in a report on Wednesday, September 20th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $273.00 price target on the stock in a report on Tuesday, October 3rd. JPMorgan Chase & Co. downgraded shares of Humana from an “overweight” rating to a “neutral” rating and set a $253.00 price target on the stock. in a report on Monday, October 9th. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $245.00 price target on shares of Humana in a report on Tuesday, October 10th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $260.10.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.18 EPS.
Several hedge funds and other institutional investors have recently modified their holdings of HUM. Koch Industries Inc. acquired a new stake in Humana during the second quarter worth about $404,000. Adviser Investments LLC acquired a new stake in Humana during the third quarter worth about $635,000. Wells Fargo & Company MN increased its position in Humana by 10.0% during the third quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock worth $402,799,000 after purchasing an additional 150,173 shares during the last quarter. Commonwealth Bank of Australia increased its position in Humana by 3.9% during the third quarter. Commonwealth Bank of Australia now owns 21,112 shares of the insurance provider’s stock worth $5,138,000 after purchasing an additional 796 shares during the last quarter. Finally, Icon Advisers Inc. Co. increased its position in Humana by 22.7% during the third quarter. Icon Advisers Inc. Co. now owns 5,400 shares of the insurance provider’s stock worth $1,316,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.
In other news, VP Timothy S. Huval sold 1,382 shares of the stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares in the company, valued at $2,843,484.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jody L. Bilney sold 7,054 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the sale, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,115 shares of company stock worth $2,501,627. Insiders own 0.80% of the company’s stock.
Humana announced that its board has initiated a stock buyback program on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.59%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.59%.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.